- Home
- HUMA vs CNTB Comparison
HUMA vs CNTB Comparison
Compare HUMA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | CNTB |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 140.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HUMA | CNTB |
|---|---|---|
| Price | $0.41 | $0.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $1.63 | ★ $5.88 |
| AVG Volume (30 Days) | ★ 5.8M | 1.5M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,038,000.00 | $64,000.00 |
| Revenue This Year | $72.32 | $11,291.47 |
| Revenue Next Year | $518.79 | $74.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.79 |
| 52 Week High | $1.78 | $3.82 |
Technical Indicators
Market Signals| Indicator | HUMA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 34.08 |
| Support Level | $0.34 | N/A |
| Resistance Level | $0.75 | $2.84 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 39.45 | 4.63 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.